<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01688570</url>
  </required_header>
  <id_info>
    <org_study_id>UL1RR031973-02</org_study_id>
    <nct_id>NCT01688570</nct_id>
  </id_info>
  <brief_title>Mechanisms of Neuromuscular Fatigue Post Stroke</brief_title>
  <official_title>Mechanisms of Neuromuscular Fatigue Post Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While baseline weakness is clearly an important factor that contributes to disability post&#xD;
      stroke, neuromuscular fatigue (the acute reduction in force production) of the paretic&#xD;
      musculature likely compounds strength deficits and further exacerbates disability. The&#xD;
      proposed study aims to improve our understanding of the mechanisms of neuromuscular fatigue&#xD;
      in people post stroke in order to optimize strength training. In healthy individuals, both&#xD;
      central (neural) and peripheral (muscle) factors are determinants of neuromuscular fatigue,&#xD;
      but preliminary data from our laboratory suggests a greater contribution of central&#xD;
      components to neuromuscular fatigue in the paretic musculature. Although cortical pathways&#xD;
      are clearly disrupted post stroke, it is likely that brainstem pathways, known to have&#xD;
      neuromodulatory effects on spinal motor circuitry, are more involved in the sustaining of&#xD;
      force in the paretic leg, compared to the non-paretic and control legs. Therefore, the&#xD;
      purpose of this proposal is to examine the role of descending neuromodulatory pathways of the&#xD;
      brainstem in neuromuscular fatigue post stroke (Aim 1) and to correlate brainstem-related&#xD;
      changes in neuromuscular fatigue to walking function (Aim 2). The investigators propose that&#xD;
      stroke survivors' decreased capability to sustain force overtime results from the diminished&#xD;
      ability of spinal motoneurons to respond to brainstem neuromodulatory inputs (serotonin&#xD;
      (5-HT) and norepinephrine (NE)). Aim 1 will quantify stroke-related decreases in motor output&#xD;
      sensitivity to a 5-HT and NE reuptake inhibitor (SNRI), serotonin antagonist, or placebo&#xD;
      during sub-maximal intermittent fatiguing knee extension contractions. If motoneurons are&#xD;
      desensitized to descending monoamines in chronic stroke patients, then they will be less&#xD;
      sensitive to the effects of drugs that increase monoamine levels. The investigators predict&#xD;
      that in response to the SNRI or serotonin antagonist, the paretic leg will show less change&#xD;
      in time to task failure and a smaller reduction in strength as compared to the non-paretic&#xD;
      and control legs. For Aim 2, the investigators predict that stroke subjects with the highest&#xD;
      walking function will demonstrate the greatest fatigue-related changes in response to the&#xD;
      SNRI. This proposal adopts an innovative model of motor impairment post stroke by including&#xD;
      the role of subcortical structures in neuromuscular fatigue.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Force generation</measure>
    <time_frame>At time of each of 4 testing sessions (all sessions within a 2 year period).</time_frame>
    <description>Sub-maximal and maximal force measurements will be made during brief contractions during each of the four testing sessions. All sessions will occur at least one week apart and within a total time span of 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surface electromyography (EMG)of lower leg muscles.</measure>
    <time_frame>EMG measurements will be made during each of the four sessions.</time_frame>
    <description>Sessions will occur at least a week apart and within a 2 year time span.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neuromuscular fatigue testing with duloxetine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyproheptadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neuromuscular fatigue testing with cyproheptadine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Neuromuscular fatigue testing with placebo dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duloxetine</intervention_name>
    <description>Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproheptadine</intervention_name>
    <description>Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.</description>
    <arm_group_label>Cyproheptadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  be at least 18 years of age&#xD;
&#xD;
          -  Cognitively able to give informed consent Stroke&#xD;
&#xD;
             -≥ 6 months post diagnosis of unilateral cortical stroke&#xD;
&#xD;
          -  residual leg paresis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  chronic low back or hip pain&#xD;
&#xD;
          -  major psychiatric disorders (e.g. depression&#xD;
&#xD;
          -  substance abuse&#xD;
&#xD;
          -  head trauma&#xD;
&#xD;
          -  neurodegenerative disorder&#xD;
&#xD;
          -  any uncontrolled medical disorder (e.g. hypertension)&#xD;
&#xD;
          -  taking any medication or supplement (e.g. St. John's Wort) that has 5-HT or NE&#xD;
             mechanisms of action(including Monoamine oxidase inhibitors (MAO) inhibitors)&#xD;
&#xD;
          -  narrow angle glaucoma&#xD;
&#xD;
          -  chronic liver or kidney disorders Stroke&#xD;
&#xD;
          -  history of multiple strokes&#xD;
&#xD;
          -  people who are unable to follow 2 step commands&#xD;
&#xD;
          -  people who cannot walk ≥ 10 ft without physical assistance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip A. Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2012</study_first_posted>
  <last_update_submitted>November 4, 2015</last_update_submitted>
  <last_update_submitted_qc>November 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Phillip Nelson, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>neuromuscular fatigue</keyword>
  <keyword>motor impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproheptadine</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

